
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is projected to return to strong growth by the second half of 2025 and continue this trend into 2026 and 2027, driven by the performance of key products such as Capvaxive and the anticipated launch of clesrovimab for RSV. With a significant focus on the Chinese market, Merck's increased partnership activity in the region is expected to boost its business development and licensing, enhancing market share in key therapeutic areas. The company's optimism surrounding Keytruda’s subcutaneous formulation and ongoing clinical trials for promising therapies like MK-8527 highlight potential revenue protection and growth opportunities amid strong product performances.
Bears say
The negative outlook on Merck & Co's stock is primarily driven by anticipated sales erosion of Keytruda due to competition from biosimilars and the impact of Medicare's IRA price negotiations, with projections indicating a decline of 58% in Keytruda sales post-loss of exclusivity. Additionally, the firm has recently experienced lowered sales expectations for its Gardasil vaccine, compounded by underperformance in new product launches like Winrevair, which fell short of estimates with actual sales of $200 million against projected figures of $256 million and $213 million. Overall, these factors have led to downward revisions in the company's valuation and price targets, reflecting heightened risks to future revenue streams.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares